Trial Profile

INTERACT- Integrated Evaluation of Resistance and Actionability Using Circulating Tumor DNA in HR Positive Metastatic Breast Cancers

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 30 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anastrozole (Primary) ; Fulvestrant (Primary) ; Letrozole (Primary) ; Abemaciclib; Palbociclib; Ribociclib
Indications Advanced breast cancer; Male breast cancer
Focus Therapeutic Use
Acronyms INTERACT

Most Recent Events

05 Dec 2024 According to ClinicalTrials.gov this trial was Terminated as Despite modifications, accrual was poor and the closed
25 Sep 2023 Status changed from recruiting to completed.
20 Apr 2023 Planned primary completion date changed from 26 Apr 2023 to 26 Apr 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com